Reviewer's report

Title: Efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration study

Version: 1 Date: 27 May 2012

Reviewer: Mark A Stein

Reviewer's report:

This paper describes the response of partial responders to amphetamine formulations who are enrolled in a clinical trial of LDX, with the main finding that they respond similar to other study participants.

Main weakness is lack of control over previous amphetamine treatment, and limited generalizability of study population. One would assume if they were doing well they would not be including in the trial, as well as those who had poor tolerability to an amphetamine product would also not be a participant.

For the clinician reading the trial, there is some reassurance that it may be worth trying LDX with a partial response to an amphetamine stimulant. However, there is no data on what the specific advantages are (i.e does it last longer, are there fewer adverse events), and why would an amphetamine versus a methylphenidate or non stimulant be preferable in a partial responder.

Article is well written.

Level of interest: An article of insufficient interest to warrant publication in a scientific/medical journal

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I have received research support from Shire and Novartis, and served as a consultant for Shire and Novartis.